Skip to content
Webinar

The $495M NEC Verdict:

Exclusive Insights into the Landmark Decision and What Firms Need to Know Before Taking on NEC Cases

Blog Post Images-2

Join us Wednesday, August 7th, at 1 p.m. ET for an exclusive webinar that delves into the landmark $495 million NEC verdict against Abbott Laboratories, the maker of Similac. This session will feature insights from THL Attorney and Lead Trial Counsel Jake Plattenberger and THL Partner Tyler Schneider.

This webinar is an invaluable opportunity for attorneys and law firm staff members to learn from the experts behind one of the most significant verdicts in recent history. Whether you are looking to navigate the complexities of NEC litigation, stay informed about major legal developments, or enhance your client intake process this session will provide the insights and actionable advice you need.

NEC Blog Post Timeline Illustration (600 x 300 px)

What You Will Learn: 

  • Overview of the Trial: Gain a detailed understanding of the trial that led to the $495 million verdict, including key strategies and pivotal moments.
  • Client Intake via SimplyConvert’s Instant Case Evaluator™: Learn how the Gill family connected with THL through our advanced client intake system, ensuring a smooth and efficient onboarding process.
  • Gathering NEC Cases: The verdict has increased interest in this case. Even with the tight NEC criteria, quick-acting firms can help hold formula makers accountable.
  • Q&A Session: Engage directly with the THL team, ask your questions, and discuss best practices for handling NEC cases.

Background of the Case:

  • Verdict Announcement: On Friday, July 26, 2024, a Missouri state court jury handed down a $495 million verdict, the first of its kind, against Abbott Laboratories over allegations that its cow's milk-based baby formula can damage a baby’s intestinal tract.
  • Damages Awarded: The St. Louis jury awarded $95 million in compensatory damages and $400 million in punitive damages to plaintiff Margo Gill. Her infant daughter developed a dangerous condition called necrotizing enterocolitis (NEC) after receiving Abbott’s Similac brand formula in a neonatal intensive care unit.
  • Trial Highlights: Attorneys argued that Abbott knew about the NEC risks but failed to disclose them adequately. Abbott claimed the injuries were due to a traumatic birthing process, not the formula. The trial took place before Judge Michael Noble.
  • Broader Context: This was the second NEC-related trial in the country. Earlier this year, an Illinois jury awarded $60 million in a similar case. Thousands of similar trials are pending, including a federal trial in the multi-district litigation scheduled for 2025.

Register Now!

Don’t miss out on this chance to elevate your legal practice and better serve your clients. Register today to secure your spot for this must-attend event.

Register Now: